Octreotide induces caspase activation and apoptosis in human hepatoma HepG2 cells. 2011

Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
Liver Research Laboratory, School of Medicine, University of Crete, Heraklion 71003, Greece.

OBJECTIVE To investigate the role of octreotide on cellular proliferation and apoptosis of human hepatoma (HepG2) cells. METHODS We studied cellular proliferation, apoptosis and the possible internal caspase-mediated apoptosis pathway involved, after treatment of HepG2 carcinoma cells with octreotide in comparison with the apoptosis caused by tumor necrosis factor-α (TNF-α). Activities of caspase-3, caspase-9, caspase-8 and caspase-2 were studied, while apoptosis was investigated through detection of DNA fragmentation and through identification of apoptotic cells with the annexin-V/propidium iodide flow cytometric method. RESULTS After an initial increase in HepG2 cellular proliferation, a significant inhibition was observed with 10⁻⁸ mol/L octreotide, while TNF-α dose-dependently decreased proliferation. Early and late apoptosis was significantly increased with both substances. Octreotide significantly increased caspase-3, caspase-8 and caspase-2 activity. TNF-α significantly increased only caspase-2. Cellular proliferation was decreased after treatment with octreotide or TNF-α alone but, in contrast to TNF-α, octreotide decreased proliferation only at concentrations of 10⁻⁸ mol/L, while lower concentrations increased proliferation. CONCLUSIONS Our findings are suggestive of caspase-mediated signaling pathways of octreotide antitumor activity in HepG2 cells, and indicate that measurements of serum octreotide levels may be important, at least in clinical trials, to verify optimal therapeutic drug concentrations.

UI MeSH Term Description Entries
D004305 Dose-Response Relationship, Drug The relationship between the dose of an administered drug and the response of the organism to the drug. Dose Response Relationship, Drug,Dose-Response Relationships, Drug,Drug Dose-Response Relationship,Drug Dose-Response Relationships,Relationship, Drug Dose-Response,Relationships, Drug Dose-Response
D004789 Enzyme Activation Conversion of an inactive form of an enzyme to one possessing metabolic activity. It includes 1, activation by ions (activators); 2, activation by cofactors (coenzymes); and 3, conversion of an enzyme precursor (proenzyme or zymogen) to an active enzyme. Activation, Enzyme,Activations, Enzyme,Enzyme Activations
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D014409 Tumor Necrosis Factor-alpha Serum glycoprotein produced by activated MACROPHAGES and other mammalian MONONUCLEAR LEUKOCYTES. It has necrotizing activity against tumor cell lines and increases ability to reject tumor transplants. Also known as TNF-alpha, it is only 30% homologous to TNF-beta (LYMPHOTOXIN), but they share TNF RECEPTORS. Cachectin,TNF-alpha,Tumor Necrosis Factor Ligand Superfamily Member 2,Cachectin-Tumor Necrosis Factor,TNF Superfamily, Member 2,TNFalpha,Tumor Necrosis Factor,Cachectin Tumor Necrosis Factor,Tumor Necrosis Factor alpha
D015282 Octreotide A potent, long-acting synthetic SOMATOSTATIN octapeptide analog that inhibits secretion of GROWTH HORMONE and is used to treat hormone-secreting tumors; DIABETES MELLITUS; HYPOTENSION, ORTHOSTATIC; HYPERINSULINISM; hypergastrinemia; and small bowel fistula. Octreotide Acetate,Compound 201-995,Octreotide Acetate Salt,SAN 201-995,SM 201-995,SMS 201-995,Sandostatin,Sandostatine,Sandoz 201-995,Compound 201 995,Compound 201995,SAN 201 995,SAN 201995,SM 201 995,SM 201995,SMS 201 995,SMS 201995,Sandoz 201 995,Sandoz 201995
D017209 Apoptosis A regulated cell death mechanism characterized by distinctive morphologic changes in the nucleus and cytoplasm, including the endonucleolytic cleavage of genomic DNA, at regularly spaced, internucleosomal sites, i.e., DNA FRAGMENTATION. It is genetically programmed and serves as a balance to mitosis in regulating the size of animal tissues and in mediating pathologic processes associated with tumor growth. Apoptosis, Extrinsic Pathway,Apoptosis, Intrinsic Pathway,Caspase-Dependent Apoptosis,Classic Apoptosis,Classical Apoptosis,Programmed Cell Death,Programmed Cell Death, Type I,Apoptoses, Extrinsic Pathway,Apoptoses, Intrinsic Pathway,Apoptosis, Caspase-Dependent,Apoptosis, Classic,Apoptosis, Classical,Caspase Dependent Apoptosis,Cell Death, Programmed,Classic Apoptoses,Extrinsic Pathway Apoptoses,Extrinsic Pathway Apoptosis,Intrinsic Pathway Apoptoses,Intrinsic Pathway Apoptosis
D049109 Cell Proliferation All of the processes involved in increasing CELL NUMBER including CELL DIVISION. Cell Growth in Number,Cellular Proliferation,Cell Multiplication,Cell Number Growth,Growth, Cell Number,Multiplication, Cell,Number Growth, Cell,Proliferation, Cell,Proliferation, Cellular
D053143 Caspase 2 A long pro-domain caspase that contains a caspase recruitment domain in its pro-domain region. Activation of this enzyme can occur via the interaction of its caspase recruitment domain with CARD SIGNALING ADAPTOR PROTEINS. Caspase 2 plays a role in APOPTOSIS by cleaving and activating effector pro-caspases. Several isoforms of this protein exist due to multiple alternative splicing of its MESSENGER RNA. Caspase 2 Subunit p12,Caspase 2 Subunit p13,Caspase 2 Subunit p18,Caspase-2,ICH-1 Protease,Pro-Caspase-2,Procaspase-2,ICH 1 Protease,Pro Caspase 2,Procaspase 2
D053148 Caspase 3 A short pro-domain caspase that plays an effector role in APOPTOSIS. It is activated by INITIATOR CASPASES such as CASPASE 9. Isoforms of this protein exist due to multiple alternative splicing of its MESSENGER RNA. CASP3,Apopain,Caspase-3,Pro-Caspase-3,Procaspase-3,Pro Caspase 3,Procaspase 3

Related Publications

Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
May 2012, Zhongguo Zhong yao za zhi = Zhongguo zhongyao zazhi = China journal of Chinese materia medica,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
December 2004, Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
September 2012, Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
January 2011, Tumori,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
January 2014, Biological & pharmaceutical bulletin,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
October 2023, Combinatorial chemistry & high throughput screening,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
January 2009, Anticancer research,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
October 2017, Experimental and therapeutic medicine,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
August 2014, BMB reports,
Nikos J Tsagarakis, and Ioannis Drygiannakis, and Antonis G Batistakis, and George Kolios, and Elias A Kouroumalis
October 2014, Natural product communications,
Copied contents to your clipboard!